Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the results of the ongoing Phase II SWOG S1702 study (NCT03499808) which examined the role of the anti-CD38 monoclonal antibody isatuximab in patients with relapsed/refractory amyloid light-chain (AL) amyloidosis. Isatuximab was well tolerated with some grade one or two infusion-related adverse events. The overall hematologic response rate was 77%, where one patient achieved hematological complete response (CR) in a median of 1.1 months. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.